Species & Strain in Fibrosis Models: Mouse vs Rat, C57BL/6

1. Why Do Identical Treatments Produce Different Results?

"I administered bleomycin, but the lungs didn't fibrose," or "CCL4 didn't induce cirrhosis." Many researchers new to in vivo preclinical testing face these frustrating issues. Often, the root cause is not faulty techniques or expired reagents, but rather an incorrect choice of animal species or genetic strain.

Organ fibrosis is not simply a mechanical injury; it is a highly regulated cascade driven by immune responses and aberrant repair mechanisms. Consequently, using animals with fundamentally different baseline immune profiles or genetic backgrounds will drastically alter the phenotype.

This article explains why the C57BL/6 mouse is often considered the "king of fibrosis," and provides expert guidance on selecting the optimal species and strain for your specific research goals.

2. Species Differences: Mouse vs. Rat

The choice between a mouse and a rat goes far beyond differences in size and husbandry costs.

Mouse (Mus musculus)

• Advantages: The unparalleled availability of genetic modification technologies (knockout/knockin/transgenic) makes mice the premier choice for functional analysis of specific molecules. Furthermore, the catalog of available antibodies, assay kits, and probes for mice is vastly superior to that for rats.
• Characteristics: Distinct immune biases between different mouse strains allow researchers to tightly control the immunological environment (e.g., Th1 vs. Th2 dominance) of their models.
• Primary Models: Bleomycin (BLM) pulmonary fibrosis, NASH/MASH diet-induced and STAM models, UUO (Unilateral Ureteral Obstruction), etc.

Rat (Rattus norvegicus)

• Advantages: The larger tissue mass and blood volume of rats mean that significantly more material can be harvested from a single animal, making them ideal for comprehensive PK/PD (Pharmacokinetics/Pharmacodynamics) analyses and toxicology testing. Additionally, certain cardiovascular and metabolic pathways in rats more closely resemble human physiology.
• Characteristics: Rats exhibit unique sensitivities in specific organ models, particularly in renal research.
• Primary Models: Adenine-induced CKD model (Rats develop consistent, progressive renal failure and severe tubulointerstitial fibrosis mimicking human CKD much more reliably than mice), heart failure-associated cardiac fibrosis, and robust CCl4-induced liver fibrosis.

3. Mouse Strain Differences: Why C57BL/6 Dominates Fibrosis Research

When utilizing mice, selecting the correct inbred strain is critical. The most influential factor determining susceptibility to fibrosis is the innate balance between Th1 (cellular immunity) and Th2 (humoral immunity) responses.

C57BL/6 (B6) Mice: The First Choice

• Immunological Profile: Th1-dominant (Pro-inflammatory). B6 mice readily produce pro-inflammatory cytokines like IFN-γ and mount aggressive inflammatory responses to tissue injury.
• Fibrosis Susceptibility: Extremely High (Susceptible). Because the initial inflammatory insult is so intense, the subsequent repair process triggers massive collagen deposition and severe fibrosis.
• Applications: The vast majority (estimated >80%) of pulmonary fibrosis (Bleomycin), MASH, and UUO models are performed on a B6 background to ensure robust and quantifiable disease progression.

BALB/c Mice: Strong Allergy, Weak Fibrosis?

• Immunological Profile: Th2-dominant. BALB/c mice readily produce IL-4 and IL-13, making them the standard choice for allergy, asthma, and parasitic infection models.
• Fibrosis Susceptibility: Relatively Low (Resistant / Less susceptible). For example, when challenged with bleomycin, BALB/c mice typically develop only mild, patchy fibrosis and demonstrate a much faster natural resolution of the disease compared to B6 mice.
• The Paradox: While Th2 cytokines (like IL-13) are generally considered pro-fibrotic downstream, in models driven by acute chemical injury (like BLM), the severe early Th1/M1 macrophage-driven inflammatory storm is the primary prerequisite for initiating the fibrotic cascade. Thus, the Th1-skewed B6 mouse paradoxically develops worse fibrosis.

Other Notable Strains

• C3H/HeJ: Carries a mutation in TLR4, rendering it resistant to LPS (endotoxin). Useful for teasing apart the contribution of innate immunity and gut-derived endotoxins in models like liver fibrosis.
• DBA/2: Gaining attention in NASH research because it exhibits a lipid metabolism and transcriptomic profile that some studies suggest more closely mimics human hepatopathology compared to B6.

Organ-by-Organ Selection Quick Reference

Organ / Model	First Choice	Alternative	Not Recommended	Rationale
Lung (BLM)	C57BL/6 mouse	—	BALB/c	Th1 acute inflammation is required for fibrotic progression
Liver (CCl4 repeated)	C57BL/6 mouse / Wistar rat	BALB/c	—	B6 for KO compatibility; rat for portal hypertension
Liver (MASH diet)	C57BL/6J (AMLN/GAN)	DBA/2	BALB/c	Nnt deletion in B6J unmasks insulin resistance
Kidney (UUO)	C57BL/6 mouse	129/Sv	BALB/c	Short-term, reproducible interstitial fibrosis
Kidney (adenine CKD)	Wistar/SD rat	C57BL/6 mouse (high dose)	—	Mouse aversion to adenine diet complicates dosing
Skin (BLM s.c.)	C57BL/6 / DBA/2	—	BALB/c	Scleroderma-like sclerosis clearer in Th1-skewed strains
Heart (TAC/AngII)	C57BL/6 mouse / SD rat	129/Sv	—	Echo functional readout easier in rats

4a. The Substrain Issue: C57BL/6J vs C57BL/6N

"B6" is often used as a single label, but C57BL/6J (JAX origin) and C57BL/6N (NIH lineage) diverge phenotypically. Key differences:

• Nnt deletion: B6J carries a 5-exon deletion in Nnt, impairing mitochondrial NADPH/glutathione metabolism. As a result, high-fat-diet-induced insulin resistance and hepatic lipid accumulation are more pronounced in B6J — a major reason B6J dominates MASH research.
• Alcohol preference and several behavioral phenotypes also differ between J and N.
• Practical recommendation: In publications, specify the substrain and vendor, e.g., C57BL/6J (JAX #000664). Simply writing "C57BL/6" is increasingly flagged by reviewers.

4b. Sex Differences: Does Fibrosis Progress Differently in Males vs Females?

Preclinical fibrosis studies have historically skewed male, but NIH has required consideration of sex as a biological variable since 2016. Key patterns:

• Liver fibrosis (CCl4/MASH): Estrogen is anti-fibrotic; female mice develop milder fibrosis. Male B6J is standard for MASH efficacy; use ovariectomized females to model postmenopausal disease.
• Pulmonary fibrosis (BLM): Males generally show more severe fibrosis, though strain-dependent. Estrogen receptor signaling appears alveolar-epithelium-protective in females.
• Renal fibrosis (UUO): Males show more intense tubulointerstitial fibrosis; testosterone depletion attenuates this.
• Cardiac fibrosis (AngII): Males exhibit greater hypertrophy and fibrosis. HFpEF models often favor females, since human HFpEF is female-predominant.

5. Examples in Validated Models

[Lung] Bleomycin-Induced Pulmonary Fibrosis

• B6 Mice: Develop severe, widespread bridging fibrosis peaking around days 14-21. The undeniable standard for testing anti-fibrotic drugs.
• BALB/c Mice: Fibrosis is localized, less severe, and resolves prematurely.
• Conclusion: To reliably measure collagen reduction (drug efficacy), C57BL/6 is mandatory.

[Liver] Carbon Tetrachloride (CCl4)-Induced Liver Fibrosis

• B6 vs. BALB/c: Literature suggests BALB/c mice may actually be more susceptible to the acute hepatotoxic necrosis of CCl4. However, repeated dosing in B6 mice reliably produces excellent bridging fibrosis, and B6 is heavily favored to match the background of knockout strains.
• Rats (Wistar / Sprague-Dawley): Often preferred over mice for advanced hepatology studies. Their larger livers allow for reliable development of "micronodular cirrhosis" after prolonged CCl4 exposure, making them superior for studying portal hypertension and systemic hemodynamics.

[Kidney] Adenine-Induced Chronic Kidney Disease (CKD)

• Rats (Wistar / SD): Feeding rats an adenine-enriched diet or administering it via oral gavage consistently leads to 2,8-DHA crystal deposition, severe tubulointerstitial fibrosis, and secondary hyperparathyroidism.
• Mice (B6 etc.): Mice have a strong aversion to adenine-enriched chow, often resulting in dramatically reduced food intake and the risk of severe weight loss/malnutrition before fibrosis fully develops. Creating this model in mice requires careful adjustment of adenine concentrations in specialized diets or consistent administration via oral gavage, making the rat model significantly more practical and robust.

[MASH] Strain and Substrain Susceptibility

MASH is one of the most strain-sensitive fibrosis fields:

• C57BL/6J (B6J): Nnt deletion drives pronounced lipid accumulation and fibrosis on AMLN/GAN/CDAHFD — the de facto standard for modern MASH research.
• C57BL/6N (B6N): Intact Nnt. On the same diet, fibrosis is milder and drug signals are harder to detect.
• DBA/2: Some studies argue it better recapitulates human MASH bile-acid and mitochondrial signatures than B6J.
• BALB/c: Th2-skewed; MASH diets yield only mild fibrosis. Not recommended.

See the MASH Model Selection Guide for deeper comparison.

6. The Right Choice is the Foundation of Success

The animal model is the foundation of your entire study. Using a strain simply because it is available, without considering its immunological background, risks wasting months of effort and valuable test compounds.

To build an optimal preclinical model, researchers should consistently evaluate and select species/strains based on three core criteria:

1. What is the target Mechanism of Action (MoA)?: Are you targeting early inflammation, late-stage collagen cross-linking, or metabolic dysfunction?
2. What are the sampling requirements?: If extensive blood sampling is needed for PK analysis alongside tissue harvesting, rats are the pragmatic choice.
3. Natural History of the Model: Will the chosen strain naturally resolve the fibrosis before your drug has a chance to show an effect?

To generate compelling, highly translational data using quantitative methods like Sirius Red Morphometry and Hydroxyproline Assays, you must start with a reliable, highly sensitive, and reproducible animal model.

7. FAQ

Q1: My transgenic line is only on a C57BL/6 background — is BLM still a good fit?

Yes, generally. B6 is highly BLM-susceptible, which is ideal for pharmacology on KO/TG lines. One caveat: tamoxifen-induced Cre systems introduce hepatic and metabolic toxicity from tamoxifen itself, so a Cre-only control arm is essential.

Q2: Mouse or rat for PK/PD studies?

Rats win on blood volume and serial sampling. However, for antibody therapeutics where cross-reactivity is species-dependent, confirm binding against the mouse vs rat target before committing. Mouse reagents (especially cross-reactive surrogate antibodies) are more broadly available.

Q3: Animals are dying earlier than expected after BLM — why?

Common causes: 1) overdose (>2.5 U/kg intratracheal in B6 raises mortality sharply); 2) inadequate anesthesia leading to aspiration; 3) substrain sensitivity (B6N reported more susceptible in some labs); 4) colony pathogens (PVM, Sendai). Start at 70-80% of published doses and optimize with a small pilot.

Q4: CCl4 — rat or mouse?

• Genetic models or higher-throughput efficacy screens → mouse (B6)
• Portal pressure, hemodynamics, serial biopsy staging → rat (SD/Wistar)
• Bridging fibrosis → nodular cirrhosis transition → rat preferred Also note: females are less susceptible to CCl4, so males are the default.

Q5: How can I run the adenine CKD model in mice?

0.2% adenine chow triggers severe food aversion. Options:

1. Drop to 0.15% adenine for 4 weeks (Diwan et al. 2018).
2. Oral gavage at 50 mg/kg/day — dose-accurate, intake-independent.
3. Switch to rats if budget and timeline permit — the most reliable path overall.

---

Related Articles

• Fibrosis Mechanisms: Myofibroblasts as Drug Targets — Molecular basis for understanding species differences
• MASH Model Selection Guide — AMLN/GAN/STAM/CDAHFD comparison
• Bleomycin Pulmonary Fibrosis Model — Standard protocol and endpoints
• UUO Renal Fibrosis Model — Surgical procedure
• Adenine CKD Model — Dosing and mouse vs rat
• Sirius Red Staining for Fibrosis Quantification — Cross-strain evaluation method
• Hydroxyproline Assay — Gold standard collagen quantification

---

References

1. Walkin L, et al. The role of matrix metalloproteinases in animal models of peritoneal fibrosis. Fibrogenesis Tissue Repair. 2013;6(1):18. PMID: 24073826
2. Peng R, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One. 2013;8(4):e59348. PMID: 23565148
3. Diwan V, et al. Adenine-induced chronic kidney disease in rats. Nephrology (Carlton). 2018;23(1):5-11. PMID: 28703447
4. Mekada K, et al. Genetic differences among C57BL/6 substrains. Exp Anim. 2009;58(2):141-149. PMID: 19448337
5. Freeman HC, et al. Deletion of nicotinamide nucleotide transhydrogenase: a new quantitative trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes. 2006;55(7):2153-2156. PMID: 16804088
6. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014;509(7500):282-283. PMID: 24834516
7. Kurtz DM, et al. The diet composition matters: impact of Western and purified diets on DBA/2J versus C57BL/6J strain susceptibility to NASH. Nutrients. 2020;12(11):3444. PMID: 33182763
8. Henderson NC, et al. Fibrosis: from mechanisms to medicines. Nature. 2020;587(7835):555-566. PMID: 33239795